Anesthetic Management of COVID-19 Associated Mucormycosis: A Narrative Review

Abstract

Severe COVID-19 disease is currently being managed with glucocorticoids. As a result, there are increasing reports of COVID-19 associated mucormycosis. (CAM) Patients with diabetes mellitus, organ transplant recipients, and in immune-compromised patients either due to cancer chemotherapy or with HIV and AIDS are at high risk of developing CAM. Pharmacotherapy with antifungal agents like Amphotericin B and surgery are the main treatment options. In this narrative review, we will discuss the challenges and anesthetic concern while managing CAM.